Rainmed Medical Limited
潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2297)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

FINANCIAL HIGHLIGHTS

	Year Ended December 31,		
	2024	2023	Change
	RMB million **(Except percentage)** **(audited)**	*RMB million* (Except percentage) (audited)	
Revenue	**39.8**	73.2	(45.6%)
Gross profit	**23.9**	48.6	(50.8%)
Gross profit margin	**60.1%**	66.3%	
Loss attributable to Shareholders of the Company	**(113.5)**	(115.8)	(2.0%)
Adjusted non-HKFRS loss attributable to Shareholders of the Company[Note]	**(112.6)**	(108.3)	4.0%
	RMB	*RMB*	
Loss per share – Basic and diluted	**(0.10)**	(0.10)	0%
Adjusted non-HKFRS loss per share – Basic and diluted	**(0.10)**	(0.09)	11.1%

The Board does not recommend payment of any final dividend for the Reporting Period.

Note: For the year ended December 31, 2024, the Group incurred loss of RMB113.5 million attributable to Shareholders of the Company. Share-based payment expenses are non-cash expenses arising from share awards and the Pre-IPO Share Option Scheme granted to certain management personnel and employees, which are commonly not included in similar non-HKFRS measures adopted by other companies in our industry. After eliminating potential impacts of certain non-cash or other expenses that do not affect our ongoing operating performance, including share-based payment expenses, the Group's adjusted non-HKFRS loss attributable to equity holders of the Company was RMB112.6 million.

The Board is pleased to announce the audited consolidated results of the Group for the Reporting Period, together with the comparative figures of the previous year.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

		Year Ended December 31,	
	Notes	**2024**	2023
		RMB'000	*RMB'000*
		(audited)	(audited)
Revenue	4	**39,824**	73,219
Cost of sales		**(15,957)**	(24,666)
Gross profit		**23,867**	48,553
Research and development expenses		**(35,444)**	(41,328)
Selling expenses		**(50,847)**	(70,869)
General and administrative expenses		**(46,993)**	(74,696)
Impairment losses of financial assets		**(78)**	(96)
Impairment losses of goodwill		**(5,778)**	–
Impairment losses of property, plant and equipment		**(12,981)**	–
Other income	5	**9,439**	5,585
Other gains – net	6	**520**	4,667
Operating loss		**(118,295)**	(128,184)
Finance income		**3,931**	12,405
Finance costs		**(936)**	(1,309)
Finance income – net		**2,995**	11,096
Loss before income tax		**(115,300)**	(117,088)
Income tax (expense)/credit	7	**(242)**	22
Loss for the year		**(115,542)**	(117,066)
Loss for the year attributable to:			
Shareholders of the Company		**(113,496)**	(115,830)
Non-controlling interests		**(2,046)**	(1,236)
		(115,542)	(117,066)
Loss per share for the year attributable to the shareholders of the Company		**(113,496)**	(115,830)
– Basic and diluted loss per share (RMB)	8	**(0.10)**	(0.10)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONTINUED)

	Year Ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
	(audited)	(audited)
Loss for the year	**(115,542)**	(117,066)
Other comprehensive income/(expense):		
Items that will not be reclassified to profit or loss		
Exchange differences arising from translation of the Company	**8,978**	5,783
Items that may be reclassified to profit or loss		
Exchange differences arising from translation of subsidiaries of the Company	**(4,415)**	(1,016)
Other comprehensive income for the year, net of tax	**4,563**	4,767
Total comprehensive expense for the year	**(110,979)**	(112,299)
Total comprehensive expense attributable to:		
Shareholders of the Company	**(108,933)**	(111,063)
Non-controlling interests	**(2,046)**	(1,236)
	(110,979)	(112,299)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	**2024** ***RMB'000*** **(audited)**	2023 *RMB'000* (audited)
ASSETS			
Non-current assets			
Property, plant and equipment		**142,308**	109,117
Right-of-use assets		**7,857**	8,534
Intangible assets		**43,184**	41,551
Goodwill		**6,813**	12,591
Deferred income tax assets		**24,630**	24,630
Other receivables	9	**356**	2,453
Prepayments		**—**	5,217
		225,148	204,093
Current assets			
Inventories		**11,048**	9,786
Trade and other receivables	9	**18,486**	10,350
Prepayments		**2,830**	13,797
Financial assets at fair value through profit or loss ("**FVTPL**")		**139,853**	135,647
Bank deposits with the maturity over three months		**11,088**	65,550
Cash and cash equivalents		**54,607**	134,085
		237,912	369,215
Total assets		**463,060**	573,308
EQUITY			
Share capital and premium		**2,786,929**	2,786,929
Accumulated losses		**(2,448,883)**	(2,335,387)
Other reserves		**68,949**	63,507
Equity attributable to the shareholders of the Company		**406,995**	515,049
Non-controlling interests		**2,917**	4,963
Total equity		**409,912**	520,012

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

	Notes	**2024** ***RMB'000*** **(audited)**	2023 *RMB'000* (audited)
LIABILITIES			
Non-current liabilities			
Borrowings		**3,893**	11,678
Lease liabilities		**685**	367
Deferred income tax liabilities		**232**	269
		4,810	12,314
Current liabilities			
Borrowings		**18,685**	3,893
Trade and other payables	11	**20,947**	29,029
Contract liabilities		**6,357**	3,984
Current income tax liabilities		**33**	13
Lease liabilities		**2,316**	4,063
		48,338	40,982
Total liabilities		**53,148**	53,296
Total equity and liabilities		**463,060**	573,308
Net current assets		**189,574**	328,233

1. General Information

Rainmed Medical Limited (the "**Company**") was incorporated in the Cayman Islands on April 9, 2021 as a company with limited liability under the Companies Law, Cap. 22 of the Cayman Islands. The address of its registered office is Campbells Corporate Services Limited, Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands. The address of its principal place of business is Room 19-108, 19/F, Cityplaza Three, 14 Taikoo Wan Road, Taikoo, Hong Kong.

The Company is an investment holding company. The Company and its subsidiaries (together, the "**Group**") are primarily engaged in research and development ("**R&D**"), manufacturing and commercialisation of medical instrument related to coronary angiography-derived fractional flow reserve ("**caFFR**") system and coronary angiography-derived index of microvascular resistance ("**caIMR**") system (the "**Listing Business**") in the People's Republic of China (the "**PRC**"), Europe and other regions.

The Company's shares have been listed on the main board of the Stock Exchange of Hong Kong Limited since July 8, 2022 (the "**Listing Date**") .

These consolidated financial statements are presented in Renminbi ("**RMB**"), unless otherwise stated.

Pursuant to a reorganization (the "**Reorganization**") in preparing for the listing of the Company's shares on the Main Board, which was completed on June 24, 2021, the Company became the holding company of the other companies comprising the Group.

2. Basis of preparation

The consolidated financial statements of the Group has been prepared in accordance with the Hong Kong Financial Reporting Standards ("**HKFRSs**") issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**"). In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and by the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at FVTPL.

The preparation of consolidated financial statements in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies.

As at December 31, 2024, the Group had a total cash and cash equivalents of approximately RMB54,607,000 and bank deposits with the maturity over three months of approximately RMB11,088,000. The directors are of the opinion that the Group has sufficient cash and cash from the redemption of financial assets at FVTPL for its daily operation for the next twelve months. Accordingly, the directors of the Company consider that it is appropriate to prepare the consolidated financial statements on a going concern basis.

3. Accounting Policies

(a) Amendments to HKFRSs that are mandatorily effective for the current year

In the current year, the Group has applied, for the first time, the following amendments to HKFRSs issued by the HKICPA which are effective for the Group's financial year beginning on January 1, 2024:

- Amendments to HKFRS 16, Lease Liability in a Sale and Leaseback
- Amendments to HKAS 1, Classification of Liabilities as Current or Non-current and the related amendments to Hong Kong Interpretation 5 (2020) Presentation of Financial Statements – Classification by the Borrower of a Term Loan that Contains a Repayment on Demand Clause
- Amendments to HKAS 1, Non-current Liabilities with Covenants
- Amendments to HKAS 7 and HKFRS 7, Supplier Finance Arrangements

The application of the amendments to HKFRSs in the current year has had no material effect on the Group's financial performance and positions for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

(b) New and amendments to HKFRSs issued but not yet effective

The following new and amendments to HKFRSs relevant to the Group have been issued but are not effective for the annual reporting period beginning on January 1, 2024 and have not been early adopted by the Group:

		Effective for annual periods beginning on or after
Amendments to HKAS 21	Lack of Exchangeability	January 1, 2025
Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments	January 1, 2026
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards – Volume 11	January 1, 2026
HKFRS 18	Presentation and Disclosure in Financial Statements	January 1, 2027
HKFRS 19	Subsidiaries without Public Accountability: Disclosures	January 1, 2027
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

The directors of the Company anticipate that, except as described below, the application of the new and amendments to HKFRSs will have no material impact on the results and the financial position of the Group in the foreseeable future.

HKFRS 18 – Presentation and Disclosure in Financial Statements

HKFRS 18 sets out requirements on presentation and disclosures in financial statements and will replace HKAS 1 Presentation of Financial Statements. HKFRS 18 introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. Minor amendments to HKAS 7 "Statement of Cash Flows" and HKAS 33 "Earnings per Share" are also made.

HKFRS 18, and the consequential amendments to other HKFRS Accounting Standards, will be effective for annual periods beginning on or after January 1, 2027, with early application permitted.

The application of HKFRS 18 is not expected to have material impact on the financial position of the Group but is expected to affect the presentation of the consolidated statement of profit or loss and other comprehensive income and consolidated statement of cash flows and disclosures in the future consolidated financial statements. The Group will continue to assess the impact of HKFRS 18 on the consolidated financial statements of the Group.

4. Segment and revenue information

(a) Description of segments and principal activities

The Group is engaged in the R&D, manufacturing, and commercialisation of medical instrument related to caFFR System and caIMR System. For management purposes, the Group is not organised into business units based on their products and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

(b) The amount of each category of revenue is as follows:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Timing of revenue recognition		
At a point in time:		
– Sales of products	**39,148**	72,684
Over time:		
– Installation and training services	**676**	535
	39,824	73,219

(c) The following table presents the analysis of contract liabilities related to the above-mentioned revenues:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Contract liabilities:		
Consideration for sales of goods	**4,262**	1,783
Consideration for installation and training services	**2,095**	2,201
	6,357	3,984

Contract liabilities of the Group mainly arise from the advance payments made by customers while the underlying products or services are yet to be delivered or provided.

(d) Revenue recognised in relation to contract liabilities

The following table shows how much of the revenue recognised in the current reporting period relates to carried-forward contract liabilities:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Revenue recognised that was included in the balance of contract liabilities at the beginning of the year:		
– Sales of goods	**1,783**	1,493
– Installation and training services	**605**	335
	2,388	1,828

(e) Geographical information

Revenue from customers by geographic location as determined by destination of delivery is as follows:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
China	**38,991**	72,743
Others	**833**	476
	39,824	73,219

As at December 31, 2024 and 2023, all of the non-current assets of the Group were located in the PRC.

(f) Information about major customers

The major customers which contributed more than 10% of the total revenue of the Group for the years ended December 31, 2024 and 2023 are listed as below:

	Year ended December 31,	
	2024	2023
Customer A	**22.15%**	—
Customer B	**13.71%**	14.22%
Customer C	—	11.30%
Total	**35.86%**	25.52%

(g) Unsatisfied performance obligations

The Group does not disclose information about remaining performance obligations as their original expected duration is less than one year as permitted under the practical expedient in accordance with HKFRS 15.

5. Other income

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Government grants	**9,439**	5,585

Government grants relating to costs are recognised in the profit or loss in the year necessary to match them with the expenses that they are intended to compensate.

6. Other gains – net

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Net foreign exchange (losses)/gains	**(657)**	1,078
Losses on disposals of property, plant and equipment	**(5)**	(11)
Fair value change in financial assets at FVTPL	**1,254**	1,059
Gain from derecognition of wealth management products	**—**	1,345
Others	**(72)**	1,196
	520	4,667

7. Income tax (expense)/credit

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Current income tax	**(279)**	(15)
Deferred income tax	**37**	37
	(242)	22

The Group's principal applicable taxes and tax rates are as follows:

(a) The Cayman Islands and BVI

The Company is incorporated in the Cayman Islands as an exempted company and is not liable for taxation in the Cayman Islands. The Group's subsidiary incorporated in the BVI is also an exempted company and is not liable for taxation in the BVI.

(b) Hong Kong

Subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at a rate of 16.5%. No provision for Hong Kong profits tax has been made as the Group did not have estimated assessable profit in Hong Kong during the years ended December 31, 2024 and 2023.

(c) Mainland China

Pursuant to the Enterprise Income Tax Law of the PRC (the "**EIT Law**") and the Implementation Rules of the EIT Law, the EIT is unified at 25% for all types of entities, effective from January 1, 2008.

Suzhou Rainmed Medical Technology Company Limited ("**Suzhou Rainmed**"), the Group's major operating subsidiary in the PRC, has obtained the approvals to become a new and high-technology enterprise in December 2021, which is effective for three years commencing on January 1, 2024 and January 1, 2021. Suzhou Rainmed are entitled to a preferential income tax rate of 15% on the estimated assessable profits for the years ended December 31, 2024 and 2023.

According to the PRC income tax law and its relevant regulations issued in 2019, entities that qualified as small and low profit enterprises are entitled to a preferential income tax rate of 5% (for taxable income less than RMB1,000,000) or 10% (for taxable income range from RMB1,000,000 to RMB3,000,000). During the year ended December 31, 2024, four (2023: four) of the PRC subsidiaries of the Group qualified as small and low profit enterprises and are entitled to the preferential income tax rate of 5%.

According to the relevant laws and regulations promulgated by the State Administration of Taxation of the PRC that has been effective from 2021 onwards, enterprises engaging in research and development activities are entitled to claim 200% of their eligible research and development expenses so incurred as tax deductible expenses when determining their assessable profits for that year ("**Super Deduction**").

8. Loss per share

(a) Basic loss per share

The calculation of basic loss per share for the year ended December 31, 2024 is based on the loss attributable to equity shareholders of the Company of RMB113,496,000 (2023: RMB115,830,000) and the weighted average of 1,167,799,000 ordinary shares (2023: 1,167,799,000 ordinary shares) in issue during the year, calculated as follows:

	Year ended December 31,	
	2024	2023
Loss attributable to shareholders of the Company (RMB'000)	**(113,496)**	(115,830)
Weighted average number of ordinary shares in issue (thousand)	**1,167,799**	1,167,799
Basic loss per share (in RMB/share)	**(0.10)**	(0.10)

(b) Diluted loss per share

The Group has potential dilutive shares throughout the years ended December 31, 2024 and 2023 related to the Pre-IPO share option scheme. For the years ended December 31, 2024 and 2023 respectively, the potential ordinary shares were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the years ended December 31, 2024 and 2023 are the same as basic loss per share.

9. Trade and other receivables

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Trade receivables (a)	**2,088**	3,691
Other receivables (b)	**16,754**	9,112
Less: non-current portion	**(356)**	(2,453)
Trade and other receivables – current portion	**18,486**	10,350

The carrying amounts of trade and other receivables were denominated in RMB.

(a) Trade receivables

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Trade receivables	**2,273**	4,093
Less: provision for impairment	**(185)**	(402)
Trade receivables – net	**2,088**	3,691

The credit period for trade receivables was generally 60 days to 180 days during the year. The ageing analysis of trade receivables based on invoice dates was as follows:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Within 30 days	**359**	1,888
31 days to 90 days	**183**	377
91 days to 180 days	**411**	384
181 days to 365 days	**611**	1,444
Over 365 days	**709**	—
	2,273	4,093

(b) Other receivables

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Deposits	**2,049**	3,251
Value-added tax recoverable	**12,730**	4,838
Others	**2,010**	1,055
	16,789	9,144
Less: provision for impairment	**(35)**	(32)
Other receivables – net	**16,754**	9,112
Less: non-current portion	**(356)**	(2,453)
	16,398	6,659

The maximum exposure to credit risk at the reporting date is the carrying value of each class of receivables mentioned above.

The carrying amounts of the Group's other receivables approximate their fair values.

10. Dividend

No dividend has been paid or declared by the Company during the years ended December 31, 2024 and 2023.

11. Trade and other payables

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Trade payables	**559**	3,447
Staff salaries and welfare payables	**5,675**	15,207
Other tax payables	**4,736**	4,252
Payables for service suppliers	**6,837**	1,117
Other accrued expenses	**3,140**	5,006
	20,947	29,029

The ageing analysis of trade payables based on invoice dates was as follows:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Within 1 year	**559**	3,447

The Group's trade and other payables are denominated in the following currencies:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
– RMB	**19,442**	19,785
– HK$	**1,505**	9,244
	20,947	29,029

MANAGEMENT DISCUSSION AND ANALYSIS

I. BUSINESS REVIEW

Founded in 2014, we are committed to becoming a global leading vascular interventional surgical robotics company, with our current focus on the design, development and commercialization of caFFR System, caIMR System and IVD. Our Core Products, caFFR System and caIMR System, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of CAD. They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. These two systems are currently utilized singularly for precision diagnosis of CAD. As FFR measures the macro-circulation of arteries which account for 5% of all arteries and IMR measures the micro-circulation of arteries which account for 95% of all arteries, therefore, using a combination of IMR and FFR can provide a comprehensive evaluation on the coronary circulation status of CAD patients. In addition, our two systems were included into the Expert Consensus on Computation of Coronary Physiological Assessment Technology in China（《中國計算冠狀動脈生理學檢測技術專家共識》）in December 2022. The Expert Consensus fills the gap of the lack of guidance and norm in the clinical application of physiological indicators calculation in the intervention of coronary heart disease in China, and provides a basis for its standardized application and expansion of the scope of application. These two systems are also expected to form the core and crucial modules for our future vascular interventional surgical robots.

Our caFFR System has obtained both certificates of CE Mark in Europe and approvals from the NMPA and several other countries. With the high accuracy rate of over 95% and convenient operation process that takes less than five minutes, our caFFR System has become a leading domestic FFR measurement product. We plan to expand the indication of our caFFR System from the current scope (covering patients with stable angina pectoris, unstable angina pectoris and post-acute phase of myocardial infarction) to further cover patients experiencing acute STEMI, acute NSTEMI and HFpEF. In addition, our caIMR System has obtained NMPA approval in April 2023, which is the only minimally invasive IMR measurement product having completed a confirmatory clinical trial globally and becomes the first minimally invasive IMR system approved for commercialization globally. Building on our caFFR System and caIMR System, and combining with the Group's other relevant products, we plan to launch our vascular interventional robot that can be used for diagnostic and therapeutic purposes by connecting and integrating all our clinical applications to automate the whole process of PCI.

In March 2023, the Group acquired 68.32% equity interests of Tianjin Yuehekang Biotechnology Co., Ltd.*（天津悦和康生物技術有限公司）("**Tianjin Yuehekang**"), which became an indirect subsidiary of the Company. Tianjin Yuehekang is a diversified high-tech enterprise engaging in the research and development, production and marketing of in vitro diagnostic products. Its principal business is in the field of biochemical in vitro diagnostic reagents. It currently has obtained 85 Class II registration certificates for biochemical diagnostic reagent products and corresponding production licenses, covering major diagnostic categories such as liver function, kidney function, blood lipids, and cardiac muscle, and has a wider coverage of products, in particular a series of innovative precision diagnostic products for cardiovascular IVD such as "coagulation" and "peptide" that are in development. The precision diagnostic products of the Group will expand from "covering all procedures of the surgery" to "check-up upon hospitalization" and "bedside check-up", further improving the Group's product portfolio.

Commercialization

In 2024, amidst the volatile market conditions, we kept on expanding the market channels of our caFFR System, caIMR System and IVD in the industry. Our revenue decreased from RMB73.2 million for the year ended December 31, 2023 to RMB39.8 million for the year ended December 31, 2024, substantially all of which were generated from the sales of our caFFR System and caIMR System, representing a year-on-year decrease of approximately 45.6%.

We have a proven track record in commercializing our Core Product, caFFR System, with a comprehensive commercialization network in China. We actively engage with KOLs – such as Dr. Ge Junbo and Dr. Huo Yong – and medical associations as part of our academic promotion and marketing strategy. As of December 31, 2024, our efficient and highly experienced sales team have established an extensive distribution network comprising 257 domestic distributors who are authorized by us to cover over 550 hospitals across 21 provinces, four autonomous regions and four municipal cities in China. With our effective and extensive sales and marketing activities, as of December 31, 2024, our caFFR System had been sold to and installed in over 750 hospitals and had been performed at over 1,450 hospitals in China, and we had completed the procurement approval procedure with over 700 hospitals in China. We have also obtained the patient self-pay prices ranging from RMB10,200 to RMB12,000 for our proprietary consumable of caFFR System in 33 provinces and regions, among which 24 provinces and regions (such as Shanghai, Guangdong, Chongqing, Henan, etc.) included our proprietary consumable of caFFR System into the medical insurance reimbursement list. Currently, we are fully promoting the implementation of including our proprietary consumable of caIMR System into the medical insurance reimbursement list.

Research and Development

Our R&D team develops innovative products focusing on the field of interventional precision diagnosis and treatment. We have a dedicated in-house R&D team primarily based in Suzhou, Jiangsu province, China, which is led by Mr. Liu Guangzhi, our chief technology officer, who has over 10 years of experience in medical device development and over 18 years of experience in software and algorithm development as well as profound management experience.

Our four R&D platforms include the medical imaging algorithm and application R&D platform, the fluid dynamics simulating calculation platform, the high-performance device R&D platform and the interventional consumables R&D platform. These platforms adhere to in-house development and innovation, capture market demand and actively explore various clinical applications for our products so as to timely upgrade our products and product candidates catering to the market demands. Our platform technologies complement each other and create a synergistic effect for our R&D efforts.

As of December 31, 2024, we had (i) 205 approved patents, including 179 approved in China, 7 approved in the U.S., 3 approved in Europe and 16 approved in Japan; (ii) 83 patents pending applications, including 75 in China and 8 overseas; (iii) 8 PCT patent applications still within the designated period; (iv) 339 registered trademarks; and (v) 15 registered software copyrights.

Manufacturing

Our commercialization efforts are well supported by our growing manufacturing capability. As of December 31, 2024, we had three manufacturing sites, two of which were located in Suzhou, Jiangsu province, China, and one was located in Tianjin, China, with a production base area of approximately 7,962 sq.m. Our manufacturing facilities are in compliance with the GMP for medical devices in China. They are expected to be able to produce 11,375 units of consoles as well as 1,130,765 units of pressure transducers (disposable consumables) and over 80 types of IVD products each year. The console and the disposable pressure transducer can be used for assembling our caFFR System and caIMR System. In addition, we acquired approximately 20,000 sq.m. of land in Suzhou, Jiangsu Province, China in May 2023 for the construction of our own manufacturing and R&D bases, which will integrate our existing manufacturing facilities and R&D facilities, enhance the overall strength of our Group and provide a convenient site for our future manufacturing pipelines.

Product and Pipeline

	Products and Product Candidates[2]		Indication	Type	Stage				Upcoming Milestone	Expected Commercial Launch
					Preclinical	Clinical	Registration	Approval		
Vascular Interventional Diagnosis and Treatment Surgical Robot	Digital Functional Diagnostic Module	caFFR System (comprising the FlashAngio caFFR System and the FlashPressure caFFR pressure transducer)	Coronary Artery Disease	III	*China*			*NMPA Approval*	N/A	Launched
				III	*China*		*Post Registration clinical trial for indication expansion [1]*		Application for mid-term completion	2025
				IIa	*Europe*		*CE Mark: exempted from clinical trial requirement*		N/A	Launched
				II	*South Korea*				Admitted to South Korea (2024Q2)	2025
				II	*United States*				Paused in September 2023	–
		caIMR System (comprising the FlashAngio caIMR System and the FlashPressure caIMR pressure transducer)	Coronary Artery Disease	III	*China*			*NMPA Approval*	N/A	Launched
				III	*China*		*Post Registration clinical trial for indication expansion [3]*		Initiation of clinical trials (2025Q2)	2028
				IIa	*Europe[2]*		*CE Mark: exempted from clinical trial requirement*		Acceptance process of registration submission	2025
				II	*South Korea*				Admitted to South Korea (2024Q2)	2025
				II	*United States*				Paused in September 2023	–
	Automated Interventional Module	Intelligent Angiographic Injection System	Vascular Disease	III		*NMPA Approval: Exempted from clinical trial requirement*			Discontinued	–
		Flash Robot Vascular Intervention Navigation Operation System	Coronary Artery Disease	III					Discontinued	–
			Peripheral Vascular Disease	III					Discontinued	–
			Neurovascular Disease	III					Discontinued	–
		Flash RDN System	Hypertension	III					Discontinued	–

- Core Product
- This device is exempted from clinical trial requirements in accordance with the Catalogue of Medical Devices Exempted from Clinical Evaluation（《免於臨床評價醫療器械目錄》）promulgated by the NMPA.

Notes:

(1) Indication expansion of caFFR System includes acute STEMI, acute NSTEMI and HFpEF.

(2) We have global commercial rights for all of our products and product candidates.

(3) Indication expansion caIMR System includes STEMI immediately after successful revascularization of targeted vessels.

caFFR System

Our caFFR System is a minimally invasive physiological assessment of coronary artery ischemia severity based on CAG images, and it is indicated for monitoring real-time aortic pressure in all stages of the cardiac cycle and assessing various physiological parameters for patients with stable angina pectoris, unstable angina pectoris and acute myocardial infarction (at least seven days after myocardial infarction). Our caFFR System is a Class III medical device under the classification criteria of the NMPA.

We commenced the confirmatory clinical trial for our caFFR System in March 2018 and completed such trial in May 2019. We obtained the CE Mark in the European Union in September 2019 and started to commercialize our caFFR System in overseas markets (such as the Czech Republic, France and Austria) in October 2019. In addition, we received the registration certificate of Class III medical device from the NMPA in December 2019 and began to commercialize our caFFR System in China in January 2020. Our R&D in relation to our caFFR System has been a continuing effort. We initiated a post-registration clinical trial in China in August 2020 to expand the indication of our caFFR System from its current scope to further cover patients experiencing acute STEMI, acute NSTEMI and HFpEF.

caIMR System

We have completed our caIMR System and obtained NMPA approval. Our caIMR System is a Class III medical device under the classification criteria of the NMPA, and such system is the only minimally invasive IMR measurement product having completed a confirmatory clinical trial globally and becomes the first minimally invasive IMR system approved for commercialization globally. In May 2022, Dr. Ge Junbo, the president of the Cardiovascular Society of the Chinese Medical Doctor Association and the chief of the Department of Cardiology in the Zhongshan Hospital of Fudan University, published the confirmatory clinical research results of our caIMR System at the European Association of Percutaneous Cardiovascular Interventions, the world's top academic conference for cardiovascular intervention. Compared with wire-based IMR, the diagnostic performance of our caIMR System indicated a diagnostic accuracy of 93.8%, sensitivity of 95.1%, and specificity of 93.1%. We obtained NMPA and ANVISA approvals for commercialization of our caIMR System in April 2023 and January 2024, respectively.

Flash Robot Vascular Intervention Navigation Operation System

The Flash Robot Vascular Intervention Navigation Operation System is our proprietary robot-assisted platform designed for navigation and operation. We plan to provide a "one-stop hybrid procedure" that can be carried out for diagnostic and therapeutic purposes at the same time in the future. Robotic-assisted operation enables precise measurement of anatomy and device positioning with the added benefit of radiation protection for physicians. Consisting of a robotic arm and a control unit (including a console and a surgical image navigation system), our Flash Robot Vascular Intervention Navigation Operation System allows physicians to precisely guide a catheter through the patient's blood vessels and further perform the operation. As of December 31, 2024, the Flash Robot Vascular Intervention Navigation Operation System was at its research suspension stage. In February 2022, our Flash Robot Vascular Intervention Navigation Operation System entered into the animal study stage and successfully passed the first animal sample trial.

IVD Products

Our IVD product business is in the field of biochemical in vitro diagnostic reagents. We currently have obtained 85 Class II registration certificates for biochemical diagnostic reagent products and corresponding production licenses, covering major diagnostic categories such as liver function, kidney function, blood lipids, and cardiac muscle, and has a wider coverage of products. Currently, a series of innovative precision diagnostic products for cardiovascular IVD such as "coagulation" and "peptide" are in development, further improving the Group's product portfolio.

WE CANNOT GUARANTEE THE FUTURE PROSPECTS OF OUR CORE PRODUCTS, caFFR SYSTEM AND caIMR SYSTEM, AND WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR OTHER PRODUCTS OR ANY OTHER PRODUCT CANDIDATES.

Outlook and Prospect

In the past year, the compliance of medical devices became stricter, and the market was full of uncertainties. We have made more arduous efforts than before. The income level was not as expected and we were making adjustments based on market conditions. Looking ahead to 2025, despite the challenging industry situation, we still need to strengthen the Company's competitive advantages in the field of FFR and IMR, increase the coverage and market strengths of IVD products, actively expand to overseas markets, enhance penetration rate in the market of mainland China, adjust marketing strategy and structure, and strive to achieve healthy growth and high-quality development throughout 2025.

II. FINANCIAL REVIEW

Revenue

Substantially all of our revenue was generated from the sales of our caFFR System and caIMR System since their commercialization. We sold substantially all of our products through our distributors for the years ended December 31, 2024 and 2023. Our contracts with distributors include a component of installing our devices and training services in addition to delivering products. We recognize revenue for sales of products upon delivery and recognize revenue for installation and training services after we have completed the relevant services. The following table sets forth a breakdown of our revenue by nature for the years indicated:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Sales of products		
– Sales of FlashAngio caFFR System	**146**	4,182
– Sales of FlashPressure caFFR pressure transducer	**30,041**	55,011
– Sales of FlashAngio caIMR system	**2,821**	6,883
– Reagents and others	**6,140**	6,608
Installation and training services	**676**	535
Total	**39,824**	73,219

Gross Profit and Gross Profit Margin

Our gross profit decreased by approximately 50.8% from RMB48.6 million for the year ended December 31, 2023 to RMB23.9 million for the year ended December 31, 2024, primarily due to the decreased sales of our FlashPressure caFFR pressure transducer, FlashAngio caFFR System, FlashAngio caIMR system. Our gross profit margin decreased from 66.3% for the year ended December 31, 2023 to 60.1% for the same period in 2024, primarily due to the change of product mix.

Research and Development Expenses

During the Reporting Period, our R&D expenses primarily consisted of (i) employee benefit expenses, including salaries, bonus and fringe benefits for R&D team; (ii) raw material costs for our R&D activities; (iii) professional service expenses, mainly representing expenses incurred in relation to (a) our intellectual property rights, such as patent application fees and patent maintenance fees, and (b) our product registration applications; (iv) clinical trial and testing expenses, including (a) payments to CROs, hospitals, SMOs and other service providers in connection with our R&D activities, and (b) our testing expenses for our products; (v) share-based payment expenses in relation to the Pre-IPO Share Option Scheme granted to certain members of our R&D team; and (vi) depreciation and amortization charges. The following table sets forth a breakdown of our R&D expenses for the years indicated:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Employee benefit expenses	**17,734**	22,213
Raw material costs	**6,525**	7,004
Professional service expenses	**1,673**	2,113
Clinical trial and testing expenses	**5,012**	4,421
Depreciation and amortization charges	**3,284**	3,617
Other expenses	**1,216**	1,352
Total	**35,444**	41,328

Our R&D expenses decreased from RMB41.3 million for the year ended December 31, 2023 to RMB35.4 million for the year ended December 31, 2024, representing a year-on-year decrease of approximately 14.2%. Such decrease was primarily due to (i) a decrease of RMB4.5 million in employee benefit expenses mainly as a result of the control of cost and expenses; and (ii) an increase of RMB0.6 million in clinical trial and testing expenses as a result of a research and development project entering a phase of design confirmation in the second half of this period.

Selling Expenses

During the Reporting Period, our selling expenses primarily consisted of (i) employee benefit expenses, including salaries, bonus and fringe benefits for sales and marketing team; (ii) marketing development expenses, primarily including expenses in connection with our sales and marketing activities, such as conference costs, travel expenses, expenses incurred for exhibitions and expenses paid to third-party research institutes for conducting market researches; (iii) share-based payment expenses in relation to share awards and the Pre-IPO Share Option Scheme granted to certain members of our sales team; and (iv) depreciation and amortization charges. The following table sets forth a breakdown of our selling expenses for the years indicated:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Employee benefit expenses	**33,989**	42,867
Marketing development expenses	**14,010**	22,629
Depreciation and amortization charges	**2,079**	2,599
Other expenses	**769**	2,774
Total	**50,847**	70,869

Our selling expenses decreased from RMB70.9 million for the year ended December 31, 2023 to RMB50.8 million for the year ended December 31, 2024, representing an decrease of approximately 28.3% as compared to the same period in 2023. Such decrease was primarily due to (i) a decrease of RMB8.9 million in employee benefit expenses mainly as a result of the control of cost and expenses; and (ii) a decrease of RMB8.6 million in marketing development expenses as a result of shrinking of sales and marketing activities.

General and Administrative Expenses

During the Reporting Period, our general and administrative expenses primarily consisted of (i) employee benefit expenses, including salaries, bonus and fringe benefits for administrative team; (ii) listing expenses; (iii) depreciation and amortization charges; (iv) share-based payment expenses in relation to share awards granted to certain members of our general management team; and (v) professional service expenses, which were primarily associated with corporate legal services. The following table sets forth a breakdown of our general and administrative expenses for the periods indicated:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Employee benefit expenses	**25,222**	46,895
Depreciation and amortization charges	**8,783**	7,893
Professional service expenses	**2,267**	6,128
Other expenses[Note]	**10,721**	13,029
Total	**46,993**	74,696

Note: Mainly included office expenses, entertainment expenses, travel expenses and property management fees.

Our general and administrative expenses decreased from RMB74.7 million for the year ended December 31, 2023 to RMB47.0 million for the year ended December 31, 2024, representing a year-on-year decrease of approximately 37.09%. Such decrease was primarily due to a decrease of RMB21.7 million in employee benefit expenses mainly in relation to an decrease in salaries and our administrative employee headcount.

Other Income

Our other income increased from RMB5.6 million for the year ended December 31, 2023 to RMB9.4 million for the year ended December 31, 2024, primarily due to an increase in government grants related to costs.

Income Tax Credit

Our income tax credit increased from RMB0.02 (credit) million for the year ended December 31, 2023 to RMB0.2 (expenses) million for the year ended December 31, 2024, primarily due to the profit generated from a subsidiary as a result of interest income.

Loss for the Year

For the reasons described above, we recorded a loss of RMB115.5 million for the year ended December 31, 2024, compared with a loss of RMB117.1 million for the year ended December 31, 2023.

Liquidity and Financial Resources

Our primary uses of cash were to fund the development of our product candidates, our clinical trials, our payment for the purchase of plant and equipment, administrative expenses, selling expenses and other recurring expenses.

For the year ended December 31, 2024, our net cash used in operating activities was RMB84.3 million, primarily because we incurred significant R&D expenses, administrative expenses and selling expenses during the Reporting Period. Our operating cash flow will continue to be affected by our operating expenses such as R&D expenses. During the Reporting Period, we mainly relied on capital contribution from Shareholders and equity financing as the main source of liquidity. Our management closely monitors the utilization of cash and cash balances and strives to maintain healthy liquidity for our business. Going forward, we believe that our liquidity requirements will be satisfied with the net proceeds from the Global Offering, our cash and cash equivalents on hand and cash generated from our operations.

For the year ended December 31, 2024, our net cash generated from investing activities was RMB6.3 million, primarily attributable to withdrawal of short-term bank deposits of RMB93.7 million, which was offset by placement of short-term bank deposits, purchase of property, plant and equipment and purchases of intangible assets of RMB35.2 million, RMB44.2 million and RMB9.6 million, respectively.

For the year ended December 31, 2024, our net cash generated from financing activities was RMB0.7 million, primarily attributable to proceeds from bank and other borrowings of RMB20.8 million, which was partially offset by repayments of bank borrowings and lease payment of RMB13.8 million and RMB5.5 million, respectively.

As at December 31, 2024, our cash and cash equivalents amounted to RMB54.6 million, representing a decrease of RMB79.5 million from RMB134.1 million as at December 31, 2023. Our net current assets decreased from RMB328.2 million as at December 31, 2023 to RMB189.6 million as at December 31, 2024, primarily attributable to the decrease in bank deposits with the maturity of over three months.

Indebtedness

As at December 31, 2024, we had an outstanding balance of borrowings of RMB22.6 million. We had unutilized bank facilities of RMB230.1 million.

Our lease liabilities decreased from RMB4.4 million as at December 31, 2023 to RMB3 million as at December 31, 2024, primarily attributable to lease payments.

Capital Commitments

As at December 31, 2024, we had capital commitments contracted but not provided for of RMB302.1 million in relation to the purchase of construction and furnishing services and equipment for the Group's production plants.

Charges on Assets

As at December 31, 2024, the Group's bank borrowings were secured by the Group's equity interest in one subsidiary of RMB26 million.

Contingent Liabilities

As at December 31, 2024, we did not have any material contingent liabilities (as at December 31, 2023: nil).

Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, we did not hold any significant investments nor conduct any material acquisitions or disposals of subsidiaries, associates or joint ventures.

Foreign Exchange Exposure

We are exposed to foreign currency risk primarily arising from cash at banks denominated in USD. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider appropriate hedging measures in the future should the need arise.

Key Financial Ratios

The following table sets forth the key financial ratios as at the dates indicated:

	As at December 31,	
	2024	2023
Quick ratio[(1)]	**4.7**	8.8
Gearing ratio[(2)]	**Not meaningful**	Not meaningful

Notes:

(1) Quick ratio is calculated by dividing current assets less inventories as of a given date by current liabilities as at such date.

(2) Gearing ratio is calculated using interest-bearing bank and other borrowings less cash and cash equivalents divided by total equity and multiplied by 100%. Gearing ratio is not meaningful as our interest-bearing bank and other borrowings less cash and cash equivalents were negative.

Future Plans for Material Investments or Capital Assets

The Group will continue to expand into the China and global markets in order to tap its internal potential and maximize Shareholders' interests. The Group will continue to drive product development within its product pipeline. The Group will continue to grow and develop through self-development, mergers and/or acquisitions. We will use various financing channels to support capital expenditures, including but not limited to internal funds and bank loans. Currently, the Group's bank credit line is sufficient.

Human Resources

As at December 31, 2024, the Group employed 270 full-time employees, all of whom were stationed in China. During the Reporting Period, the Group's total employee benefit expenses (including (i) wages, salaries and bonuses; (ii) social security costs; (iii) employee benefits; and (iv) equity-settled share awards) amounted to approximately RMB0.9 million. We recruit our employees based on a number of factors, including their work experience, educational background and the requirements of the relevant vacancies. We invest in continuing education and training programmes for our management staff and other employees to continuously improve their skills and knowledge. We provide regular feedback to our employees, as well as internal and external training in various areas such as product knowledge, project development and team building. We also assess the performance of our employees to determine their salaries, promotion opportunities and career development. In accordance with the relevant PRC labour laws, we enter into individual employment contracts with our employees covering matters such as tenure, wages, bonuses, employee benefits, workplace safety, confidentiality obligations, non-competition and grounds for termination. In addition, we are required under PRC law to make contributions to statutory employee benefit plans (including pension plans, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and housing funds) at certain percentages of the salaries (including bonuses and allowances) of our employees, up to a maximum amount specified by the local government. The adoption of the Pre-IPO Share Option Scheme of 707,628 Shares (or 35,381,400 Shares as adjusted after the capitalization issue) as further described in the Prospectus was approved at the Board meeting of the Company held on December 10, 2021. The purpose of the Pre-IPO Share Option Scheme is to attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group. The Pre-IPO Share Option Scheme also helps the Company to modernize its remuneration practices and improve the balance of interests among Shareholders, operation and execution management by aligning their interests.

SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

No significant events occurred since the end of the Reporting Period.

FINAL DIVIDEND

The Board does not recommend payment of any final dividend for the Reporting Period (for the year ended December 31, 2023: nil).

AGM AND CLOSURE OF THE REGISTER OF MEMBERS

The Company will hold the AGM on Friday, June 27, 2025. The notice of the AGM will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.rainmed.com) and dispatched to the Shareholders in the manner as required by the Listing Rules in due course.

The register of members of the Company will be closed from Tuesday, June 24, 2025 to Friday, June 27, 2025, both days inclusive, in order to determine the identity of the Shareholders who are entitled to attend the AGM. To be eligible to attend the AGM, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited at 17th Floor, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Monday, June 23, 2025.

CORPORATE GOVERNANCE

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as set out in Appendix C1 to the Listing Rules.

During the year ended December 31, 2024, the Company complied with all code provisions of the CG Code except for the deviation as disclosed below.

Pursuant to code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Huo Yunfei currently serves as the chairman of the Board and the chief executive officer of the Group ("**CEO**"). He is responsible for overall strategic planning and decision-making, execution, operation and management of the Company. Although this constitutes a deviation from code provision C.2.1 of the CG Code, the Board considers that vesting the roles of both chairman of the Board and CEO in Mr. Huo Yunfei has the benefit of ensuring consistent leadership and more effective and efficient overall strategic planning of the Group. The balance of power and authority is ensured by the operation of the Board, which comprises experienced and diverse individuals. The Board currently comprises three executive Directors, three non-executive Directors and three independent non-executive Directors. Therefore, the Board possesses an independent element in its composition.

The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding securities transactions by the Directors. Having made specific enquiry with the Directors, all Directors confirmed that they have complied with the standards set out in the Model Code throughout the year ended December 31, 2024.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the year ended December 31, 2024, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares).

AUDIT COMMITTEE

The Board has established the Audit Committee, comprising three independent non-executive Directors, i.e., Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Chen Xuefeng, with Mr. Liu Shuen Kong serving as the chairman. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Group, overseeing the audit process, and performing other duties and responsibilities as assigned by the Board.

The Audit Committee has reviewed the accounting principles and practices adopted by the Group with the management and the Company's external auditors, and has reviewed the annual results of the Group for the year ended December 31, 2024.

SCOPE OF WORK OF THE AUDITORS

The figures in respect of the Group's consolidated income statement, statement of comprehensive income, consolidated balance sheet and the related notes thereto for the year ended December 31, 2024 as set out in this annual results announcement have been agreed by the Group's auditors, SHINEWING (HK) CPA Limited (the "**SHINEWING**"), to the amounts set out in the Group's audited consolidated financial statements for the year ended December 31, 2024 prepared in accordance with HKFRSs. The work performed by SHINEWING in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by SHINEWING on this annual results announcement.

PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT AND 2024 ANNUAL REPORT

This annual results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.rainmed.com), and the 2024 annual report containing all the information required by the Listing Rules will be dispatched to the Shareholders and published on the respective websites of the Stock Exchange and the Company in due course.

DEFINITIONS

In this annual results announcement, the following expressions shall have the meanings set out below, unless the context otherwise requires:

"AGM"	the 2024 annual general meeting of the Company to be held on Friday, June 27, 2025
"Audit Committee"	the audit committee of the Board
"Board of Directors" or "Board"	the board of Directors
"BVI"	the British Virgin Islands
"CAD"	coronary artery diseases, a condition where the major blood vessels supplying the heart are narrowed to reduce blood flow that can cause chest pain and shortness of breath
"caFFR"	coronary angiography-derived fractional flow reserve, a novel minimally invasive index to determine the FFR in patients with stable or unstable angina
"CAG"	coronary angiography, a percutaneous procedure that uses contrast dye and X-ray images to detect CAD
"caIMR"	coronary angiography-derived index of microvascular resistance, which is proposed for physiological assessment of microvascular diseases in coronary circulation
"CE Mark"	a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, which for the purpose of this announcement and for geographical reference only, Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company" or "our Company"	Rainmed Medical Limited（潤邁德醫療有限公司）, an exempted company with limited liability incorporated in the Cayman Islands on April 9, 2021

"confirmatory clinical trial"	a controlled clinical trial of a medical device product designed to demonstrate statistically significant clinical efficacy and safety of such product as used in human patients (in conjunction with the performance of a therapeutic procedure) for regulatory approval of such product
"Core Product"	has the meaning ascribed thereto in Chapter 18A of the Listing Rules, which, for purposes of this announcement, refers to each of caFFR System and caIMR System
"Director(s)"	the director(s) of the Company
"FFR"	fractional flow reserve, a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis at maximal hyperemia to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle and diagnose myocardial ischemia
"Global Offering"	has the meaning as ascribed to it in the Prospectus
"GMP"	good manufacturing practice, the quality assurance that ensures that medical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the product specification
"Group", "our Group", "we", "us" or "our"	our Company and its subsidiaries from time to time or, where the context so requires, in respect of the period prior to our Company became the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of our Company at the relevant time
"HFpEF"	heart failure with preserved ejection fraction, a condition which occurs when the lower left chamber (left ventricle) is not able to fill properly with blood during the diastolic (filling) phase and the amount of blood pumped out to the body is less than normal
"HKFRS"	Hong Kong Financial Reporting Standards, as issued from time to time by the Hong Kong Accounting Standards Board
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC

"IMR"	index of microcirculatory resistance, the quantitative assessment of the minimum microcirculatory resistance in a target coronary arteriolar territory
"IVD"	in vitro diagnostic
"KOL(s)"	key opinion leader(s), renowned physicians who are able to influence their peers' medical practice
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange (as amended, supplemented or otherwise modified from time to time)
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"NMPA"	National Medical Products Administration of the PRC （國家藥品監督管理局）, the successor to the China Food and Drug Administration（國家食品藥品監督管理總局）
"NSTEMI"	non-ST segment elevation myocardial infarction, a heart attack that occurs without ST segment elevation on the electrocardiogram
"PCI"	percutaneous coronary intervention, a percutaneous procedure to open a narrowed or blocked coronary artery and restore arterial blood flow to heart tissue that does not involve open-chest surgery
"PCT"	the Patent Cooperation Treaty
"Preferred Share(s)"	has the meaning as ascribed to it in the Prospectus
"Pre-IPO Share Option Scheme"	the share option scheme adopted by the Company on December 10, 2021
"Prospectus"	the prospectus of the Company dated June 27, 2022 in relation to the Global Offering
"R&D"	research and development

"Reporting Period"	the year ended December 31, 2024
"RMB"	Renminbi, the lawful currency of the PRC
"Series Angel-1 Preferred Shares"	the series Angel-1 preferred share of our Company with a par value of HK$0.0001 each
"Series Angel-2 Preferred Shares"	the series Angel-2 preferred share of our Company with a par value of HK$0.0001 each
"Series A Preferred Shares"	the series A preferred share of our Company with a par value of HK$0.0001 each
"Series A+ Preferred Shares"	the series A+ preferred share of our Company with a par value of HK$0.0001 each
"Series B Preferred Shares"	the series B preferred share of our Company with a par value of HK$0.0001 each
"Series C-1 Preferred Shares"	the series C-1 preferred share of our Company with a par value of HK$0.0001 each
"Series C-2 Preferred Shares"	the series C-2 preferred share of our Company with a par value of HK$0.0001 each
"Series D Preferred Shares"	the series D preferred share of our Company with a par value of HK$0.0001 each
"Share(s)"	ordinary share(s) with a par value of HK$0.0001 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"SMO"	site management organization, an organization that provides clinical trial related services to medical device companies
"sq.m."	square meter, a unit of area
"STEMI"	ST segment elevation myocardial infarction, which occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules

"Suzhou Rainmed"	Suzhou Rainmed Medical Technology Co., Ltd. (蘇州潤邁德醫療科技有限公司), a limited liability company incorporated under the laws of PRC on December 5, 2016, being a wholly-owned subsidiary of our Company
"U.S. dollars", "US$" or "USD"	United States dollars, the lawful currency of the United States
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"%"	per cent

* The English translations of company names in Chinese which are marked with "*" are for identification purpose only.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, March 31, 2025

As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Lyu Yonghui and Ms. Gu Yang as executive Directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Chen Xuefeng as independent non-executive Directors.